Articles from Ethris

Ethris GmbH, a clinical-stage biotechnology company pioneering next-generation RNA therapeutics and vaccines, today announced a strategic collaboration with Thermo Fisher Scientific, the world leader in serving science, to provide a fully integrated mRNA solution to biopharmaceutical developers.

Ethris GmbH, a clinical-stage biotechnology company pioneering next-generation RNA therapeutics and vaccines, today announced that it was awarded a €10 million grant from EU4Health, the EU’s largest health programme committed to a healthier European Union. The funding will support NoVir, a comprehensive project including several preclinical and clinical studies to evaluate the potential of ETH47, Ethris’ lead, first-in-class mRNA-based antiviral therapy. Designed as a broad-spectrum antiviral with a virus- and mutation-independent mechanism of action, ETH47 offers a promising approach for pandemic preparedness.

Ethris, a clinical-stage biotechnology company pioneering next-generation RNA therapeutics and vaccines, and Lonza, one of the world’s largest contract development and manufacturing organizations (CDMOs), today announced a collaboration to develop room-temperature stable, spray-dried formulations of mRNA-based vaccine candidates, designed for mucosal delivery that offer a promising approach to combat respiratory diseases.

Ethris GmbH, a leading biotechnology company pioneering next-generation RNA therapeutics and vaccines, today announced promising topline data from the completed Phase 1 clinical trial of its lead mRNA therapeutic candidate, ETH47, in healthy volunteers. Designed to address the upstream trigger of asthma exacerbations, ETH47 encodes interferon lambda (IFNλ), a protein essential for viral immunity in the respiratory tract. These topline results provide the first clinical validation of Ethris’ pioneering targeted RNA therapeutic approach and its ability to induce a downstream cascade of antiviral interferon-stimulated genes locally following nasal administration. Thomas Langenickel, MD, Chief Medical Officer at Ethris, presented the results on January 30th, 2025, at the mRNA-Based Therapeutics Summit Europe in Frankfurt, Germany.

Ethris GmbH, a leading biotechnology company pioneering transformative messenger RNA (mRNA) therapeutics, announced today that it has raised $26.3 Million (€23.3 Million) in a Series B financing round led by Laureus Capital. The proceeds of the Series B will advance the company’s lead programs ETH47 - a broad anti-viral immune modulator - and ETH42 - a protein-replacement therapy for primary ciliary dyskinesia (PCD) - into clinical studies, further advance its proprietary and differentiated mRNA and lipidoid nanoparticle (LNP) delivery platforms and increase its manufacturing capabilities. In conjunction with the financing, Dr. Christian Wawrzinek, Founder of Laureus Capital, will join Ethris as Managing Director and Chief Corporate Strategy Officer and support Ethris with a range of activities including corporate strategy, operational planning, and long-term growth opportunities.